| Subject: | New Safety Information For Innohep (tinzaparin sodium injection) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 2 Dec 2008 - 04:00 pm |
| Audience: Hematological and Nephrological healthcare professionals, hospital risk managers The FDA has received information about the clinical study, Innohep in Renal Insufficiency Study (IRIS), that was stopped in February 2008 by the study's Data Safety Monitoring Committee because of an interim finding of an increase in all-cause mortality in patients who received Innohep. Information on the patients enrolled in the study, on the heparin used to manufacture Innohep, and on the heparin... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
